猪癌症模型为评估设备、手术和局部治疗等干预措施提供了一个有价值的平台，而这些干预措施通常很难在小鼠模型中进行测试。除了与人类在体型和解剖学上相似之外，与小鼠模型相比，猪在遗传学、免疫、药物代谢和代谢率方面与人类具有更大的相似性，这增加了它们的转化相关性。本综述重点关注 Oncopig 癌症模型，这是一种旨在重现人类癌症的基因工程猪模型。 Oncopig 拥有一个在 Cre-Lox 系统控制下表达致癌突变体 KRAS 和 TP53 的转基因盒，可以在时间和空间上控制肿瘤诱导。它的多功能性使得多种癌症模型的开发成为可能，包括肝癌、胰腺癌、肺癌和膀胱癌。作为人类癌症的临床相关模型，Oncopig 解决了未满足的临床需求，并为推进临床前癌症研究和治疗开发带来了巨大希望。

Porcine cancer models offer a valuable platform for evaluating interventions such as devices, surgeries, and locoregional therapies, which are often challenging to test in mouse models. In addition to size and anatomical similarities with humans, pigs share greater similarities in genetics, immunity, drug metabolism, and metabolic rate with humans as compared to mouse models, increasing their translational relevance. This review focuses on the Oncopig Cancer Model, a genetically engineered porcine model designed to recapitulate human cancer. Harboring a transgenic cassette that expresses oncogenic mutant KRAS and TP53 under control of a Cre-Lox system, the Oncopig allows temporal and spatial control of tumor induction. Its versatility has enabled the development of diverse cancer models including liver, pancreatic, lung, and bladder cancer. Serving as a clinically relevant model for human cancer, the Oncopig addresses unmet clinical needs and holds immense promise for advancing preclinical cancer research and therapeutic development.